Tempus AI, Inc. (NASDAQ: TEM)

Tempus AI Inc is a technology company that focuses on healthcare by creating intelligent diagnostics through the application of artificial intelligence in medicine. The company builds a platform that connects laboratory results with patient clinical data to personalize test results and guide treatment decisions. Its core activities include operating high throughput laboratories that perform genomic and molecular testing and developing software tools that integrate multi modal data for research and clinical use.

The company generates revenue primarily from two sources. First it provides diagnostic testing services to hospitals physicians and other healthcare providers and bills insurance or patients directly. Second it licenses de identified data and offers software and analytics services to pharmaceutical and biotechnology companies through its data and applications product line. Revenue also comes from contracts for clinical trial matching and other research services.

The company operates through the following segments: Diagnostics and Data and applications.

• The Diagnostics segment operates the company’s laboratory network that conducts next generation sequencing polymerase chain reaction and other molecular pathology tests for oncology hereditary neuropsychiatry and cardiology patients. It links each test result to the patient’s clinical history including treatment outcomes and adverse events to create personalized reports that improve therapeutic decision making. The segment sells its services to hospitals physicians genetic counselors and also to pharmaceutical firms that use the tests as companion diagnostics or for research.

• The Data and applications segment licenses de identified clinical molecular and imaging data to drug developers and provides software tools such as Hub Lens and Notebooks for data analysis. It also offers applications that use artificial intelligence to match patients to clinical trials to identify care gaps and to generate algorithmic diagnostics for oncology cardiology and other diseases. Revenue is generated through data licensing agreements subscription fees and service contracts with biopharma companies.

Tempus holds a distinctive position in the precision medicine market due to its ability to combine large scale laboratory testing with a proprietary data platform that links molecular results to real world clinical information. Its main competitors in diagnostics include Foundation Medicine Caris Life Sciences Guardant Health Natera and Quest Diagnostics. In the data and services arena it competes with Flatiron Health IQVIA ConcertAI and various contract research organizations. The company’s competitive advantage stems from its network effects where each additional data point improves the accuracy of its tests and the value of its database making it harder for rivals to replicate.

The company serves a broad range of customers including hospitals physician groups academic medical centers and pathology laboratories that order its diagnostic tests. It also works with nineteen of the twenty largest public pharmaceutical companies and has strategic collaborations with firms such as AstraZeneca GlaxoSmithKline and Recursion Pharmaceuticals. Additionally its data and analytics products are used by biotechnology firms research institutions and contract research organizations seeking to access its curated multimodal database.